Revenue Update on Aeglea BioTherapeutics, Inc. – Common Stock(NASDAQ:AGLE)

Aeglea BioTherapeutics, Inc. – Common Stock(NASDAQ:AGLE) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 23, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $1.247M. Analysts estimated a revenue of $3.360M. The revenues were -62.89% below the estimates. Earnings per share were $-0.33. The reported EPS was above estimates by 28.26%. Analysts had estimated an EPS of $-0.46.

Aeglea BioTherapeutics, Inc. – Common Stock (AGLE) made into the market gainers list on Fridays trading session with the shares advancing 0.68% or 0.05 points. Due to strong positive momentum, the stock ended at $7.37, which is also near the day’s high of $7.47. The stock began the session at $7.32 and the volume stood at 1,52,784 shares. The 52-week high of the shares is $12.75 and the 52 week low is $3.66. The company has a current market capitalization of $99 M and it has 1,34,52,260 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Apr 14, 2016, Eli & Co Lilly (10% owner) purchased 500,000 shares at $10.00 per share price.Also, On Apr 12, 2016, Anthony Quinn (director) purchased 10,000 shares at $10.00 per share price.On Apr 12, 2016, Russell J. Cox (director) purchased 7,000 shares at $10.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Add Comment